2026-07-01 · antipsychotics, olanzapine, clozapine, aripiprazole, SGA, weight gain, metabolic syndrome · 15 min read

Which antipsychotic causes the most weight gain?

Olanzapine and clozapine sit at the top of every ranking. Allison 1999 in the American Journal of Psychiatry was the landmark meta-analysis that put clozapine at ~4.5 kg and olanzapine at ~4.2 kg over 10 weeks alone, and Huhn 2019 in The Lancet — the most recent 32-drug network meta-analysis — confirmed the same order at longer follow-up, with both drugs reliably producing 4 to 7 kg of gain over 12 months and often more in first-episode patients. Bak 2014 in PLoS One's 6-month naturalistic cohort saw the same pattern with parallel A1c and lipid deterioration. Do not stop or switch on your own — clozapine in particular is only prescribed after other antipsychotics have failed, and self-discontinuation carries a very high relapse risk. Bring the weight concern to the prescribing psychiatrist so a within-class switch, a metformin add-on, or a GLP-1 medication can be discussed safely.

Which antipsychotic is best for weight?

Aripiprazole, ziprasidone, lurasidone, brexpiprazole, and cariprazine are the consistently weight-favorable second-generation options — typically 0.5 to 1.5 kg over 12 months in Leucht 2013's Lancet network meta-analysis and Huhn 2019's updated version. Aripiprazole is the most commonly used of these in North America and is the go-to switch target in Stroup 2011's CATIE-switch trial in the American Journal of Psychiatry, which showed 2 to 3 kg of loss and modest lipid improvement when patients on olanzapine, quetiapine, or risperidone were switched to aripiprazole. Lurasidone has similar metabolic advantages plus a lower prolactin signal. These agents are not weight-loss drugs, and none of them will produce meaningful loss on their own — the point is choosing an effective medication that is less likely to add weight in the first place, not treating weight with an antipsychotic switch.

Should I switch to aripiprazole?

Sometimes — when psychosis or mood is stable, when efficacy allows it, and only with your psychiatrist. Stroup 2011's CATIE-switch trial in the American Journal of Psychiatry randomized adults with metabolic risk to switch from olanzapine, quetiapine, or risperidone to aripiprazole and saw about 2 to 3 kg of loss and modest lipid improvement without significant worsening of psychiatric symptoms on average. Switching is not appropriate during an acute episode, in the first 6 to 12 months after stabilization on an effective agent, or after prior aripiprazole trials failed. Clozapine is a special case — it is reserved for treatment-resistant schizophrenia and is uniquely effective at reducing all-cause mortality (Tiihonen 2009 The Lancet), so a switch away from clozapine is rarely the right move. In that setting the standard approach is metformin or GLP-1 layering, not discontinuation.

How much weight will I gain on olanzapine?

Expect 4 to 7 kg over the first 12 months on average, with most of it accumulating in the first 3 to 6 months and then plateauing (Allison 1999 American Journal of Psychiatry; Bak 2014 PLoS One; Huhn 2019 The Lancet). First-episode antipsychotic-naive patients gain the most — Perez-Iglesias 2014 in Schizophrenia Bulletin documented up to 15 percent of baseline body weight in the first year in this group. Alongside the scale change, olanzapine can shift A1c, fasting glucose, LDL, and triglycerides even before large weight gain appears (Newcomer 2007 CNS Drugs), which is why baseline and 3-, 6-, and 12-month metabolic monitoring per the ADA/APA/AACE/NAASO 2004 consensus is standard of care. Track weight weekly, not daily, and bring the trajectory plus a repeat fasting lipid and A1c to your psychiatrist at month 3 so any switch, add-on, or lifestyle intensification can be discussed on data.

Can I take a GLP-1 medication with clozapine?

The early trial evidence is reassuring but the decision belongs with your care team. Larsen 2017's randomized trial in JAMA Psychiatry gave liraglutide 3.0 mg to adults on clozapine or olanzapine and saw about 5.3 kg of placebo-adjusted loss over 16 weeks with improved A1c and no significant worsening of psychiatric symptoms. Siskind 2021 in JAMA Network Open extended the signal to semaglutide in a schizophrenia cohort, and Whicher 2021 in Diabetes, Obesity and Metabolism reported real-world semaglutide outcomes in severe mental illness. The Wadden 2024 SELECT psychiatric post-hoc in JAMA Internal Medicine — the largest semaglutide dataset for suicidality tracking — found no excess events versus placebo. Practical caveats: active suicidality, anorexia nervosa, and bulimia nervosa are contraindications; nausea can stack with clozapine's constipation; and the prescribing psychiatrist and primary-care prescriber both need to be in the loop before starting.

What about metformin — does it work for antipsychotic weight gain?

Yes, modestly but reliably. Jarskog 2013's randomized trial in the American Journal of Psychiatry gave metformin 500 mg titrated to 2 g per day to adults who had gained weight on antipsychotics and saw about 3 kg of placebo-adjusted loss at 16 weeks, plus improvements in insulin sensitivity and waist circumference. Praharaj's meta-analytic work and multiple subsequent trials have confirmed the effect across olanzapine, clozapine, and other second-generation agents. Metformin is the most-supported pharmacologic add-on when the antipsychotic cannot be safely switched. It is generally well tolerated — main side effects are GI upset in the first few weeks and rare lactic acidosis in severe kidney impairment — and it costs a few dollars a month. It is a low-cost, evidence-backed lever that is still under-used, and it stacks safely with a GLP-1 when one is later added.

Is the weight gain from my illness or from the drug?

Almost always both, and the mix shifts over time. De Hert 2011 in Nature Reviews Endocrinology and De Hert 2009 in Schizophrenia Research documented that people with schizophrenia and bipolar disorder carry an elevated baseline rate of metabolic syndrome, insulin resistance, and abdominal obesity independent of medication — driven by activity levels, diet quality, smoking, sleep, and possibly shared biology. Then the antipsychotic layers on top through H1-histamine and 5HT2C-serotonin appetite pathways (Kroeze 2003 Neuropsychopharmacology; Newcomer 2007 CNS Drugs) and, on olanzapine and clozapine specifically, direct effects on hypothalamic AMPK signaling (Kim 2007 PNAS) and hyperinsulinemia via M3 muscarinic activity. In first-episode antipsychotic-naive patients the drug signal dominates in year one (Perez-Iglesias 2014 Schizophrenia Bulletin). Both levers matter; the treatment plan should address both, not just one.

Do I need metabolic bloodwork on antipsychotics?

Yes. The ADA/APA/AACE/NAASO 2004 consensus statement and the APA 2020 Practice Guideline for the Treatment of Patients With Schizophrenia both call for baseline weight, waist circumference, blood pressure, fasting glucose (or A1c), and fasting lipid panel, then a repeat at 3 months, 6 months, and annually — with more frequent checks on olanzapine and clozapine. NICE 2014 CG178 in the UK is aligned. This matters because Newcomer 2007 in CNS Drugs documented that some patients on olanzapine or clozapine develop hyperglycemia, insulin resistance, or even diabetic ketoacidosis before substantial weight gain appears (Koller 2001 American Journal of Medicine). The monitoring is not optional. If your prescriber has not ordered it, ask — and bring the results to the appointment where you discuss any switch, metformin add-on, or GLP-1 conversation.

Antipsychotics and Weight Gain: Olanzapine, Clozapine, and What Helps

Quick stats

• US adults on at least one antipsychotic: ~1.6% overall, higher within severe mental illness
• Olanzapine and clozapine 12-month weight gain: typically +4 to +7 kg (Bak 2014 PLoS One; Huhn 2019 Lancet)
• Aripiprazole and lurasidone 12-month weight gain: typically +0.5 to +1.5 kg (Leucht 2013 Lancet; Huhn 2019)
• Metformin add-on effect size: ~3 kg placebo-adjusted loss at 16 weeks (Jarskog 2013 Am J Psychiatry)
• GLP-1 add-on effect size in olanzapine/clozapine users: ~5 kg placebo-adjusted loss at 16 weeks (Larsen 2017 JAMA Psychiatry)
• 988 Suicide & Crisis Lifeline: call or text 988 (US) for any thoughts of self-harm

The honest picture, in one paragraph

Antipsychotics are not interchangeable for body weight. Allison 1999 (American Journal of Psychiatry) — the landmark meta-analysis of second-generation antipsychotics — put clozapine at roughly 4.5 kg and olanzapine at roughly 4.2 kg of gain at only 10 weeks; Leucht 2013 (The Lancet) and Huhn 2019 (The Lancet) network meta-analyses of 15 and 32 drugs respectively confirmed the same ordering at longer follow-up. Bak 2014 (PLoS One) added a 6-month naturalistic cohort that quantified the parallel A1c and lipid changes drug by drug. The 12-month between-drug spread runs roughly 5 to 7 kg from the highest to the lowest-risk agents. Do not stop your antipsychotic on your own — abrupt discontinuation in schizophrenia and bipolar disorder carries very high relapse and hospitalization risk, and clozapine is uniquely effective at reducing all-cause mortality in treatment-resistant illness (Tiihonen 2009 The Lancet). The right approach is to keep the medication working and address weight through the evidence-based add-ons below.

How antipsychotics are organized

Antipsychotics are organized by generation and receptor profile — particularly H1 histamine, 5HT2C serotonin, and M3 muscarinic activity — which predicts most of the weight signal.

If your regimen includes a mood stabilizer (lithium, valproate, lamotrigine) or an antidepressant on top of the antipsychotic, the bipolar disorder and weight loss and antidepressants and weight changes guides cover how the layers stack.

Why some antipsychotics drive weight gain and others don’t

1. H1 histamine and 5HT2C serotonin receptor binding

Kroeze 2003 (Neuropsychopharmacology) mapped receptor-binding affinities across dozens of psychiatric drugs and found H1 histamine affinity correlates almost linearly with short-term weight gain. Olanzapine and clozapine sit at the top; aripiprazole, ziprasidone, and lurasidone at the bottom. Newcomer 2007 (CNS Drugs) added the 5HT2C axis, where antagonism reduces satiety signaling and raises the appetite set point. The same biology that helps olanzapine and clozapine treat refractory illness is what drives the appetite pressure.

2. M3 muscarinic activity → hyperinsulinemia and impaired glucose disposal

De Hert 2011 (Nature Reviews Endocrinology) reviewed the M3 muscarinic pathway: olanzapine and clozapine both antagonize pancreatic M3 receptors in a way that impairs insulin secretion and glucose disposal independent of weight gain. This is why Newcomer 2007 documented cases of hyperglycemia and even diabetic ketoacidosis on these two drugs before substantial weight change, and why Koller 2001 (American Journal of Medicine) built the FDA’s early safety case.

3. Direct hypothalamic effect on AMPK and appetite

Kim 2007 (PNAS) showed olanzapine activates hypothalamic AMPK — a central appetite regulator — driving hyperphagia beyond receptor-level effects at the periphery. This is the animal-model correlate of what patients describe as “unusual constant hunger” in the first weeks.

4. Illness itself carries an elevated metabolic baseline

De Hert 2009 (Schizophrenia Research) and De Hert 2011 documented that severe mental illness carries elevated rates of abdominal obesity, insulin resistance, and metabolic syndrome independent of medication — driven by activity, diet quality, smoking, sleep, and possibly shared biology. This baseline is why lifestyle work matters even on the lowest-risk antipsychotics.

How much each drug typically shifts weight, A1c, and lipids

This table is the honest 2026 lookup. Use it for the conversation with your prescriber — not for self-directed switching.

5-step antipsychotic-and-weight protocol

Step 1: Confirm the indication and the drug — do not self-discontinue

APA 2020 Practice Guideline for the Treatment of Patients With Schizophrenia and NICE 2014 CG178 are aligned and blunt: abrupt antipsychotic discontinuation carries very high relapse and hospitalization risk, and clozapine in particular is uniquely tied to reduced all-cause mortality in treatment-resistant illness (Tiihonen 2009 The Lancet). The protocol begins with a psychiatrist conversation, not a pill cut. If you have any thoughts of self-harm, call or text 988.

Step 2: Ask about a within-class switch once symptoms are stable

Stroup 2011 (American Journal of Psychiatry) CATIE-switch randomized adults with metabolic risk from olanzapine, quetiapine, or risperidone to aripiprazole and saw 2 to 3 kg of loss and modest lipid improvement without significant psychiatric worsening on average. Leucht 2013 confirmed the switch targets — aripiprazole, lurasidone, cariprazine, brexpiprazole, ziprasidone — as reasonable choices when efficacy allows. Switching is not appropriate during an acute episode or in the first 6 to 12 months after stabilization on an effective agent.

Step 3: Metformin add-on if switching is not appropriate

Jarskog 2013 (American Journal of Psychiatry) titrated metformin from 500 mg to 2 g per day in adults who had gained weight on antipsychotics and saw about 3 kg of placebo-adjusted loss at 16 weeks, plus improved insulin sensitivity. This is the most-supported pharmacologic add-on when the antipsychotic itself cannot be switched. It stacks safely with a GLP-1 later.

Step 4: GLP-1 add-on if metabolic risk stays high

Larsen 2017 (JAMA Psychiatry) gave liraglutide 3.0 mg to adults on clozapine or olanzapine and saw ~5.3 kg placebo-adjusted loss and A1c benefit over 16 weeks with no psychiatric worsening. Siskind 2021 (JAMA Network Open) and Whicher 2021 (Diabetes, Obesity and Metabolism) extended the semaglutide signal to schizophrenia and severe mental illness respectively. The Wadden 2024 SELECT psychiatric post-hoc in JAMA Internal Medicine — the largest semaglutide suicidality dataset — found no excess events versus placebo. Coordinate with the psychiatrist before starting; active suicidality, anorexia nervosa, and bulimia nervosa are contraindications. See GLP-1 medications compared and weight loss drug safety for medication-specific detail.

Step 5: Anchor on protein, movement, sleep, and metabolic labs

Protein 1.2–1.6 g/kg/day, a Mediterranean or DASH eating pattern, resistance training twice a week, sleep hygiene, and annual metabolic labs per the ADA/APA/AACE/NAASO 2004 consensus and Correll 2020 (World Psychiatry). Sedating agents reduce non-exercise activity, so a structured routine matters more than a gym program. See mediterranean diet weight loss, preserve muscle during weight loss, and sleep, stress, and weight management.

What treatments actually do — comparison

Special situations

Clozapine and weight — the hardest case

Clozapine is the only antipsychotic proven to reduce all-cause mortality in treatment-resistant schizophrenia (Tiihonen 2009 The Lancet), and it cannot be switched away from lightly. Patients on clozapine have failed at least two adequate trials of other antipsychotics, and the mortality benefit is meaningful. That means the standard approach to clozapine-related weight gain is layering — metformin per Jarskog 2013 first, then a GLP-1 per Larsen 2017 and Siskind 2021 if metabolic risk stays high — not discontinuation. Clozapine also carries specific safety monitoring: absolute neutrophil count for agranulocytosis, cardiac monitoring for myocarditis in the first 8 weeks, and vigilance for opioid-additive constipation, which can progress to ileus. GLP-1 nausea and clozapine constipation both push toward slower titration and active bowel management. Coordinate with the prescribing psychiatrist and, where relevant, a metabolic or endocrine consult.

First-episode psychosis and antipsychotic-naive weight trajectory

Perez-Iglesias 2014 (Schizophrenia Bulletin) documented the steepest weight trajectory in first-episode antipsychotic-naive patients: up to 15 percent of baseline body weight in year one, with the largest gains in the first 3 months. This population is where early metabolic monitoring and lifestyle bundling matter most, and where a lower-risk agent (aripiprazole, lurasidone) is worth strong consideration up front. Buchanan 2010 PORT and APA 2020 both emphasize this window. Baseline weight, waist, glucose, and lipids at initiation, then again at 3, 6, and 12 months, per the ADA/APA/AACE/NAASO 2004 consensus.

Children and adolescents

Correll 2009 (JAMA) SATIETY study followed antipsychotic-naive youth and documented larger, faster weight gain than in adults across olanzapine, quetiapine, risperidone, and aripiprazole — with olanzapine reaching ~8.5 kg at 12 weeks. AAP and AACAP position statements are aligned on preferring aripiprazole where efficacy allows, on early metabolic monitoring, and on structured family-based lifestyle work. See adolescent and teen weight management for the broader framework.

Bipolar maintenance layering

Many patients are on an antipsychotic plus a mood stabilizer. Vieta 2018 (The Lancet) covered the maintenance evidence base, and Cipriani 2011 (The Lancet) ordered mood stabilizers vs antipsychotics by weight signal — lithium and valproate both carry weight and metabolic signals of their own that stack with the antipsychotic. The bipolar disorder and weight loss guide covers the mood-stabilizer side; the switch strategy on the antipsychotic layer is the same as above.

GLP-1 and antipsychotic safety

The trial evidence in severe mental illness is short but reassuring. Larsen 2017, Siskind 2021, and Whicher 2021 all show effect size in olanzapine and clozapine users comparable to the general population, with no consistent psychiatric worsening. The Wadden 2024 SELECT psychiatric post-hoc in JAMA Internal Medicine — the largest suicidality-tracking dataset to date — found no excess events versus placebo. Explicit contraindications: active suicidality, anorexia nervosa, bulimia nervosa, personal or family history of medullary thyroid carcinoma or MEN2. Coordinate the psychiatrist and the GLP-1 prescriber before starting, hydrate aggressively, and titrate slowly if the patient is already on constipating medications.

Red flags — when to see a doctor

If you are having thoughts of self-harm or suicide, call or text 988 (Suicide & Crisis Lifeline) right now, or go to the nearest emergency department.

• Fever, muscle rigidity, altered mental status, or autonomic instability — possible neuroleptic malignant syndrome; emergency evaluation.
• New tongue, face, or limb movements you cannot control — possible tardive dyskinesia; urgent psychiatry review.
• New polyuria, polydipsia, blurred vision, or unexplained fatigue on olanzapine or clozapine — check for new-onset diabetes or DKA (Koller 2001 American Journal of Medicine).
• Chest pain, shortness of breath, or flu-like illness in the first 8 weeks of clozapine — possible myocarditis; urgent evaluation. Any fever on clozapine also needs an urgent ANC check for agranulocytosis.
• Any thoughts of self-harm or a plan to stop your medication on your own — call or text 988 and reach your prescriber the same day.
• Rapid unintentional weight loss, new vomiting, or persistent nausea — check adherence, hydration, and for hyperglycemia or DKA; do not assume it is the GLP-1.

How this connects to the rest of the site

Antipsychotic weight questions overlap with several clusters on the site. For the mental-health context, see schizophrenia, antipsychotics, and weight loss and bipolar disorder and weight loss. If an antidepressant is layered on top, antidepressants and weight changes covers the drug-by-drug picture. For medication options, see prescription weight loss medications, GLP-1 medications compared, and weight loss drug safety. For the everyday routine — food, movement, sleep — see mediterranean diet weight loss, preserve muscle during weight loss, and sleep, stress, and weight management.

Antipsychotics and Weight FAQ

Which antipsychotic causes the most weight gain? Olanzapine and clozapine — typically 4 to 7 kg over 12 months.

Which antipsychotic is best for weight? Aripiprazole, lurasidone, ziprasidone, brexpiprazole, cariprazine — 0.5 to 1.5 kg over 12 months.

Should I switch to aripiprazole? Only with your psychiatrist; CATIE-switch showed 2 to 3 kg loss without psychiatric worsening on average.

How much weight will I gain on olanzapine? Expect 4 to 7 kg over 12 months, most in the first 3 to 6 months.

Can I take a GLP-1 medication with clozapine? For many patients yes; coordinate the psychiatrist and monitor for constipation.

What about metformin? Yes — Jarskog 2013 showed ~3 kg placebo-adjusted loss at 16 weeks.

Is the weight gain from my illness or from the drug? Both — illness carries an elevated metabolic baseline, drug layers on top, and metabolic bloodwork at baseline, 3, 6, and 12 months per ADA/APA 2004 and APA 2020 catches problems early.